[Performance of point-of-care testing for cervical cancer screening]

Cervical cancer remains a significant public health concern globally, particularly in regions with limited access to traditional screening methods. While conventional diagnostic tools like PCR and HPV testing are effective, they require laboratory infrastructure and time for results. This gap motivated a search for alternative screening methods that can be deployed in resource-limited settings. Prior research has shown that point-of-care testing (POCT) can offer rapid results, but its accuracy in detecting cervical abnormalities has not been fully established. No prior work had resolved how POCT compares to gold-standard methods like histopathology and PCR in real-world settings. The need for a portable, efficient screening tool led to this investigation. Researchers aimed to assess whether POCT could serve as a reliable alternative in cervical cancer screening. The study focused on evaluating POCT's diagnostic performance in both self-sampled and physician-collected specimens. This work addresses a critical need for accessible and accurate screening in underserved populations.

This study aimed to evaluate the performance of point-of-care testing (POCT) for cervical cancer and precancerous lesion screening. The specific problem addressed was whether POCT could reliably detect cervical intraepithelial neoplasia grade 2 and above (CIN2+). The motivation stemmed from the limitations of traditional diagnostic methods, which require laboratory processing and delay treatment decisions. Researchers wanted to determine if POCT could provide a faster, more accessible alternative for cervical cancer screening. The study compared POCT's diagnostic accuracy with that of HPV testing and PCR in both self-sampled and physician-collected specimens. The goal was to assess whether POCT could maintain high sensitivity and specificity in real-world clinical settings. The study also aimed to compare performance metrics across sampling methods to determine optimal use cases. This investigation sought to provide evidence for POCT's potential in improving cervical cancer screening accessibility.

The study involved 470 women from two cohorts in Xiangyuan county, China. Participants were selected using simple random sampling from a self-sampling group and a physician-sampling group. Cervical cells were collected either by the participants themselves or by gynecologists. All samples were first tested using point-of-care testing (POCT). Women with positive POCT results were immediately referred for colposcopy. Subsequently, all samples were tested using careHPV and PCR methods for comparison. Women with POCT-negative but careHPV or PCR-positive results were invited for a follow-up visit for colposcopy and punch biopsy. Histopathological diagnosis served as the gold standard for evaluating diagnostic accuracy. Sensitivity and specificity were calculated for each testing method. Receiver operating characteristic (ROC) curves were used to compare the accuracy of POCT with careHPV and PCR tests.

Among the 470 participants, the median age was 51 years. In the self-sampling group, POCT demonstrated 100% sensitivity (95% CI: 56.56%-100.00%) for detecting CIN2+. However, its specificity was only 28.95% (95% CI: 22.97%-35.76%). The POCT HPV16/18 test showed similar sensitivity but higher specificity of 89.47% (95% CI: 84.30%-93.08%). The area under the curve (AUC) for self-sampling POCT HPV16/18 was 0.947 (95% CI: 0.910-0.985), outperforming careHPV and PCR. In the physician-sampling group, POCT had 100% sensitivity (95% CI: 64.57%-100.00%) and 55.85% specificity (95% CI: 49.83%-61.70%). The HPV16/18 test in this group had lower sensitivity (71.43%, 95% CI: 35.90%-91.76%) but higher specificity (92.45%, 95% CI: 88.63%-95.06%). The AUC for physician-sampling POCT HPV16/18 was 0.819, which was not significantly different from the self-sampling group (P=0.217). These results suggest that POCT HPV16/18 is a promising screening tool.

The authors propose that POCT HPV16/18 testing is an effective method for cervical cancer screening. They suggest that this approach offers relatively high sensitivity and specificity, particularly when compared to conventional methods like careHPV and PCR. The study found that POCT HPV16/18 performed well in both self-sampled and physician-collected specimens. The authors highlight that the AUC for POCT HPV16/18 was higher than that of careHPV and PCR in the self-sampling group. They propose that POCT could serve as a viable alternative in resource-limited settings where access to laboratory testing is limited. The authors suggest that the high sensitivity of POCT makes it suitable for initial screening. They propose that the higher specificity of POCT HPV16/18 could reduce unnecessary referrals for colposcopy. The authors conclude that POCT HPV16/18 is a reliable and efficient screening method.